ABBVIE INC

AbbVie’s $11 billion bid for Apogee Therapeutics could reshape the biologics market—adding a long‑acting, low‑frequency therapy for inflammatory diseases and boosting AbbVie’s portfolio and patient outcomes.

AbbVie’s CLL14 Phase III results show venetoclax‑obinutuzumab gives eight‑year disease control with fewer side‑effects, reshaping first‑line CLL care.

AbbVie’s 45‑53% 2024‑26 rally is driven by strong immunology sales, but a negative equity balance raises risk; new oncology (Epcotinly) and neuromodulation (TrenibotulinumtoxinE) trials signal promising growth, while investors must watch regulatory …

AbbVie’s new data shows patients favor natural, holistic aesthetics; its inclusion in income‑focused ETFs highlights stable growth, while obesity‑drug shifts drive competitive strategy.

AbbVie’s new bispecific antibody and trispecific T‑cell engager could replace Humira’s revenue, offering breakthrough 15%‑plus survival gains in solid tumors and multiple‑myeloma while navigating pricing, patent cliffs and strategic M&A to sustain g…

AbbVie’s upcoming EHA conference data reveals a mixed oncology outlook: new ADCs and bispecifics promise growth, but regulatory, patent, and competitive risks loom—investors face a complex balance between dividend stability and emerging blood‑cancer…

AbbVie’s strategic growth blends pipeline expansion, disciplined acquisitions, and share buybacks—yet faces patent, regulatory, and competition risks that could shape its next‑quarter value.

AbbVie’s latest wins—NICE approval for its ovarian‑cancer drug Elahere and a promising dopamine‑D3 modulator for GAD—show how the company is expanding its oncology and mental‑health portfolios while navigating tough regulatory landscapes.

AbbVie’s new ADC, DECNUPAZ, gains U.S. approval for blastic plasmacytoid dendritic cell neoplasm—first outpatient CD123‑targeted therapy showing durable responses across all patient groups.

FDA approves AbbVie’s DECNUPAZTM for BPDCN, delivering durable outpatient responses with manageable safety, marking a breakthrough in rare hematologic oncology.